ScholarIQanswers from OpenAlex & ORCID
Joyce F. Liu
ResearcherPublications, citations & collaboration network
Joyce F. Liu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Joyce F. Liu have?
ScholarIQindexed works
Joyce F. Liu has 559 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Joyce F. Liu have?
ScholarIQcitation count
Joyce F. Liu has 19,097 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Joyce F. Liu?
ScholarIQh-index
Joyce F. Liu has an h-index of 62 in OpenAlex.
What is the i10-index of Joyce F. Liu?
ScholarIQi10-index
Joyce F. Liu has an i10-index of 147 in OpenAlex.
What is the ORCID of Joyce F. Liu?
ScholarIQorcid
The ORCID for Joyce F. Liu is on the source record.
What is the OpenAlex record for Joyce F. Liu?
ScholarIQopenalex
The OpenAlex for Joyce F. Liu is on the source record.
What are the most-cited papers on Joyce F. Liu?
ScholarIQmost cited works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, Val Gebski, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedländer, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray‐Coquard, Susana Banerjee, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Patricia Pautier, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Joyce F. Liu, Haider Mahdi, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac‐Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsíros, Jennifer L. Burns, Anita M. Engh
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, John McNamara, Elizabeth Lowe, Mei-Lin Ah-See, Kathleen N. Moore, on behalf of the SOLO1 Investigators
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Gary S. Leiserowitz, Joyce F. Liu, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac‐Lima, Steven W. Remmenga, John O. Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsíros, Mary A. Dwyer, Lisa E. Hang